NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial

By afschroeder • February 14, 2026

Macarulla T, Cid RP, Womack MS, Gracian AC, Zervoudakis A, Hatoum H, Chung V, Patel A, Paulson AS, Pant S, O'Reilly EM, Hubner RA, Van Cutsem E, Bekaii-Saab T, Zhang L, Li J, Chen H, Maxwell F, Wainberg ZA, Melisi D. NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial. ESMO Open. 2026 Feb 12;11(3):106043. doi: 10.1016/j.esmoop.2025.106043. Epub ahead of print. PMID: 41687160.

Tags: age, Hematology/Oncology, Liposomal irinotecan, mPDAC, NALIRIFOX, NAPOLI 3, pancreatic ductal adenocarcinoma, Publications

Related Posts

Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer

Choueiri TK, Merchán J, Patnaik A, Drakaki A, Rini BI, Rha SY, Lee JL, Ornstein MC, Kumar R, Hwang C, Shao Y, Park SH, Barata[...]

Inhibition of Acetyl-CoA-carboxylase induces endoplasmic reticulum stress and augments the efficacy of anti-cancer therapies

Shan NL, Balinda H, Dai J, Wang Y, Lin HK, Marczyk M, Espinoza Campos G, Umlauf S, McDermott MSJ, Colorado I, Lang SM, Surovtseva YV,[...]

Early-Onset Gastric Cancer as a High-Risk Disease Entity in the United States: Clinicopathologic Features, Regional Variation, and Outcomes

Castillo DR, Shah P, Tai D, Guo M, Hazeltine M, Guzman S, Park D, Mannan R, Xing Y, Brar G, Raoof M, Eng C, Wu[...]